277
Participants
Start Date
September 13, 2021
Primary Completion Date
April 7, 2025
Study Completion Date
June 10, 2025
Anifrolumab
Intravenous infusion (IV)
placebo
Intravenous infusion (IV)
Research Site, Taipei
Research Site, New Taipei City
Research Site, Taoyuan District
Research Site, Manila
Research Site, Quezon City
Research Site, Lipa City
Research Site, Iloilo City
Research Site, Seoul
Research Site, Bangkok
Research Site, Taipei
Research Site, Suwon
Research Site, New Taipei City
Research Site, Taichung
Research Site, Taichung
Research Site, Kaohsiung City
Research Site, Beijing
Research Site, Beijing
Research Site, Beijing
Research Site, Beijing
Research Site, Beijing
Research Site, Shenyang
Research Site, Shengyang
Research Site, Chuangchun
Research Site, Shanghai
Research Site, Nanjing
Research Site, Wuxi
Research Site, Suzhou
Research Site, Bengbu
Research Site, Jinan
Research Site, Binzhou
Research Site, Jining
Research Site, Linyi
Research Site, Zaozhuang
Research Site, Tianjin
Research Site, Hangzhou
Research Site, Wenzhou
Research Site, Nanchang
Research Site, Xiamen
Research Site, Changsha
Research Site, Hengyang
Research Site, Wuhan
Research Site, Wuhan
Research Site, Zhengzhou
Research Site, Xinxiang
Research Site, Luoyang
Research Site, Nanyang
Research Site, Guangzhou
Research Site, Guangzhou
Research Site, Shenzhen
Research Site, Jieyang
Research Site, Guilin
Research Site, Nanchong
Research Site, Kunming
Research Site, Lanzhou
Research Site, Yinchuan
Research Site, Ürümqi
Research Site, Baoding
Research Site, Baotou
Research Site, Changchun
Research Site, Hong Kong
Research Site, Shijiazhuang
Research Site, Hong Kong
Research Site, Davao City
Research Site, Gwangju
Research Site, Seoul
Lead Sponsor
AstraZeneca
INDUSTRY